August 28, 2017 10:31 AM EDT
News Briefing

Bay­er, J&J eye block­buster sup­ple­men­tal OK for Xarel­to; Set­Point rais­es $30M for bio­elec­tron­ics

Shehla Shakoor

Managing Director

⇨ The an­ti-clot ther­a­py Xarel­to from Bay­er and J&J may have a much brighter fu­ture now that re­searchers have post­ed its ef­fect on pre­vent­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

A service from the Financial Times